← Back to guidelines
Cardiology54 papers

Atherosclerosis of left coronary artery

Last edited: 4/22/2026

Overview

Atherosclerosis of the left coronary artery involves the buildup of plaque within the arterial walls, leading to reduced blood flow and potentially myocardial infarction or angina. 1

Diagnosis

  • Clinical Presentation: Symptoms may include angina pectoris, dyspnea, and atypical chest pain.
  • Imaging Techniques: Coronary angiography remains the gold standard for visualizing plaque and assessing stenosis 1.
  • Non-Invasive Imaging: Coronary computed tomography angiography (CTA) can identify plaque burden and calcification 1.
  • Intravascular Ultrasound (IVUS): Useful for detailed assessment of plaque composition and intimal disruption in specific cases, though more commonly applied to other arteries like pulmonary 3.
  • Management

  • Pharmacotherapy:
  • - Statins: Reduce cholesterol levels and stabilize plaques (e.g., atorvastatin 80 mg daily) 1. - Antiplatelet Agents: Aspirin or P2Y12 inhibitors (e.g., clopidogrel 75 mg daily) to prevent thrombosis 1.
  • Lifestyle Modifications: Smoking cessation, dietary changes, and increased physical activity 1.
  • Revascularization: Coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) for significant stenosis 1.
  • Special Populations

  • Comorbidities: Immune markers like increased CD4+ T cells may indicate heightened immune activity in hypertensive patients with atherosclerosis, though specific to renal arteries 2.
  • Key Recommendations

  • Utilize coronary angiography for definitive diagnosis of left coronary artery atherosclerosis 1.
  • Initiate statin therapy targeting LDL cholesterol reduction for plaque stabilization 1 (Evidence: Strong).
  • Consider antiplatelet therapy to reduce thrombotic events in patients with significant coronary stenosis 1 (Evidence: Strong).
  • Evaluate and manage hypertension aggressively, given its association with heightened immune activity in atherosclerotic disease 2 (Evidence: Moderate).
  • References

    1 Fasihi A, Heydari-Zarnagh H, Zahedi M, Goudarzian M, Kafashzadeh M, Meshkani SE et al.. Study and Characterization of Long Non-coding RUNX1-IT1 among Large Artery Atherosclerosis Stroke Patients Based on the ceRNA Hypothesis. Journal of molecular neuroscience : MN 2021. link 2 Kotliar C, Juncos L, Inserra F, de Cavanagh EM, Chuluyan E, Aquino JB et al.. Local and systemic cellular immunity in early renal artery atherosclerosis. Clinical journal of the American Society of Nephrology : CJASN 2012. link 3 Kravitz KD, Scharf GR, Chandrasekaran K. In vivo diagnosis of pulmonary atherosclerosis. Role of intravascular ultrasound. Chest 1994. link

    Original source

    1. [1]
      Study and Characterization of Long Non-coding RUNX1-IT1 among Large Artery Atherosclerosis Stroke Patients Based on the ceRNA Hypothesis.Fasihi A, Heydari-Zarnagh H, Zahedi M, Goudarzian M, Kafashzadeh M, Meshkani SE et al. Journal of molecular neuroscience : MN (2021)
    2. [2]
      Local and systemic cellular immunity in early renal artery atherosclerosis.Kotliar C, Juncos L, Inserra F, de Cavanagh EM, Chuluyan E, Aquino JB et al. Clinical journal of the American Society of Nephrology : CJASN (2012)
    3. [3]
      In vivo diagnosis of pulmonary atherosclerosis. Role of intravascular ultrasound.Kravitz KD, Scharf GR, Chandrasekaran K Chest (1994)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG